At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 41 enrolled
Drug / intervention
Midazolam +1 moredrug
Likely dose
Midazolam 0.045 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder
In Brief
A Phase 2 clinical trial evaluating Midazolam and Ketamine for Stress Disorders, Post-Traumatic and 3 related conditions. Completed, enrolled 41 participants across 1 site.
Detailed Summary
The objective of the proposed study is to test if a single IV dose of ketamine (0.5 mg/kg) decreases symptoms of PTSD.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStress Disorders, Post-Traumatic, PTSD, Depression, Anxiety Disorder
CountriesUnited States
CollaboratorsUnited States Department of Defense
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2008
Enrollment StartJan 2009
Primary CompletionSep 2013
TodayJul 2026
First PostedSep 9, 2008
Enrollment StartJan 1, 2009
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 17.8 years ago
Interventions
Midazolamdrug
single dose 0.045 mg/kg IV infused over 40 minutes
Ketaminedrug
Single dose 0.5 mg/kg IV (in the vein) infused over 40 minutes